Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
BUSINESS
Eisai Halts Epilepsy Drug Studies after Death in Japan PI
Eisai said on July 30 that it has discontinued a Japan PI study for its next-generation AMPA receptor antagonist E2082 after a healthy volunteer subject died in June following its dosing. The drug’s PII program in the US has also…
To read the full story
Related Article
- MHLW Revises Safety Guidance on FIH Studies Following Death of Subject
January 6, 2020
- Eisai Discontinues Development of Epilepsy Drug after Death in PI; “Will Never Be Administered to Humans in the Future”
January 6, 2020
- MHLW Panel Concerned about Further Clinical Trial for Eisai’s Investigational Epilepsy Drug Following Death
December 23, 2019
- Causal Link between Eisai’s Epilepsy Drug and Trial Death Can’t Be Ruled Out: MHLW
December 2, 2019
- After Death in First-in-Human Study, MHLW Needs to Release Info. to Alleviate Concerns about Participation in Studies
August 26, 2019
BUSINESS
- AbbVie Aims to Double Japan Sales to 200 Billion Yen by 2030: Local Chief
May 31, 2023
- Jeremy Grossas to Head Up Merck Biopharma Japan
May 30, 2023
- Nobelpharma Gets EU Nod for Hyftor
May 30, 2023
- Pfizer Japan Files RSV Vaccine for 60 Years of Age and Older
May 29, 2023
- Chugai’s FoundationOne Liquid Wins Approval as Tabrecta CDx
May 29, 2023
President Joe Biden enacted the Inflation Reduction Act (IRA) on August 16, 2022, significantly affecting Medicare prescription drug coverage and introducing targeted changes to Medicaid, the Children’s Health Insurance Program, and private health insurance. In January 2023, the Centers for…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…